Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion type Assertion NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_head.
- NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion description "[Dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor ([HER]-1/EGFR, HER-2, and HER-4) tyrosine kinase inhibitor, demonstrated antitumor activity in Western patients with non-small-cell lung cancer (NSCLC) at a dose of 45 mg once daily.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_provenance.
- NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion evidence source_evidence_literature NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_provenance.
- NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion SIO_000772 25521398 NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_provenance.
- NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion wasDerivedFrom befree-2016 NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_provenance.
- NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_assertion wasGeneratedBy ECO_0000203 NP1249193.RAbsXlIquhaHc_ht-tkWjKU1Wy_hD-gfq8Juh8JGD_jcA130_provenance.